z-logo
Premium
The perils of inhibiting deficient factors
Author(s) -
Sayar Z.,
Speed V.,
Patel J. P.,
Patel R. K.,
Arya R.
Publication year - 2018
Publication title -
journal of thrombosis and haemostasis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.947
H-Index - 178
eISSN - 1538-7836
pISSN - 1538-7933
DOI - 10.1111/jth.14195
Subject(s) - rivaroxaban , medicine , warfarin , atrial fibrillation , prothrombin complex concentrate , anticoagulant , edoxaban , surgery
Essentials Anticoagulation in patients with factor X deficiency is an evidence‐poor area. A patient with factor X deficiency was anticoagulated with warfarin followed by rivaroxaban. Warfarin may be a safer anticoagulant option than rivaroxaban in hereditary factor X deficiency. A baseline coagulation screen should be performed prior to commencement of anticoagulation.Summary We report a case of a previously undiagnosed factor X deficiency in an 83‐year‐old man who had no previous bleeding history despite multiple hemostatic challenges. He was anticoagulated with warfarin for atrial fibrillation without bleeding complications; however, major hemorrhage occurred soon after a switch to rivaroxaban.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom